RxDoctor Payments Data

Thet Zaw, MD

Nephrology · Douglas, GANPI 1750690277

Payments from drug & device makers

$4,242in general payments, 2019–2025

Across 191 payments — averaging $22.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Amgen$489
  • OPKO Pharmaceuticals, LLC$484
  • Bayer$421
  • Daiichi Sankyo Inc.$420
  • Aurinia Pharma U.S., Inc.$312
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$3,72388%
  • Education$51912%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,242 in reported general payments places this provider in the 70th percentile of 388 nephrology providers in Georgia.

See all nephrology providers in Georgia

Medicare billing

Part B allowed, 2024
$289,517
Medicare patients
434
Services billed
1,747

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KrystexxaPegloticase43$1,347,619
RayaldeeCalcifediol215$284,706
JynarqueTolvaptan12$242,882
XphozahTenapanor Hcl40$213,967
FarxigaDapagliflozin Propanediol172$135,751
LokelmaSodium Zirconium Cyclosilicate67$67,156
VelphoroSucroferric Oxyhydroxide16$56,018
KerendiaFinerenone49$40,031
VeltassaPatiromer Calcium Sorbitex17$17,453
JardianceEmpagliflozin20$14,497
Calcium Acetate138$12,637
Sevelamer Carbonate66$12,592
DapagliflozinDapagliflozin Propanediol14$7,869
LinzessLinaclotide13$7,492
Clonidine23$2,393

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenKrystexxa$489$1,347,61943 claims
OPKO Pharmaceuticals, LLCRayaldee$484$284,706215 claims
Otsuka America Pharmaceutical, Inc.Jynarque$113$242,88212 claims
AstraZenecaFarxiga, Lokelma$1,015$202,906239 claims
Fresenius USA Marketing, Inc.Velphoro$64$56,01816 claims
BayerKerendia$421$40,03149 claims
Boehringer IngelheimJardiance$16$14,49720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 388 nephrology providers in Georgia.

Other nephrology in Douglas

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →